Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to a push by Donald Trump to lower US weight-loss drug prices, rising...
<p>Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition </p><p>The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to a push by Donald Trump to lower US weight-loss drug prices, rising competition and the loss of key patent protections.</p><p>Denmark’s Novo , once the <a href="https://www.theguardian.com/business/2023/sep/09/wegovy-the-slimming-drug-that-keeps-denmarks-economy-growing">poster-child for the growth in weight-loss treatments</a>, said sales this year were likely to fall between 5% and 13%, despite the <a href="https://www.theguardian.com/business/2026/jan/05/novo-nordisk-launches-wegovy-weight-loss-pill-us-price-war">launch of its new Wegovy pill in the US</a>. Its share price plummeted 18% on Wednesday morning, erasing all gains so far this year. In the past year the stock has lost nearly 50% of its value.</p> <a href="https://www.theguardian.com/business/2026/feb/04/wegovy-ozempic-forecast-revenue-share-price-drop">Continue reading...</a>
Read the full article at:
The Guardian World →